Avelumab plus talazoparib in patients with advanced solid tumors: the JAVELIN PARP medley nonrandomized controlled trial
TA Yap, A Bardia, M Dvorkin, MD Galsky… - JAMA …, 2023 - jamanetwork.com
Importance Preclinical data suggest that poly (ADP-ribose) polymerase (PARP) inhibitors
have synergistic activity when combined with immune checkpoint inhibitors (ICIs); however,
it is unknown which tumor types or molecular subtypes may benefit from this combination.
Objective To investigate responses associated with the combination of avelumab and
talazoparib in different tumor types and/or molecular subtypes. Design, Setting, and
Participants In this phase 1b and 2 basket nonrandomized controlled trial, patients with …
have synergistic activity when combined with immune checkpoint inhibitors (ICIs); however,
it is unknown which tumor types or molecular subtypes may benefit from this combination.
Objective To investigate responses associated with the combination of avelumab and
talazoparib in different tumor types and/or molecular subtypes. Design, Setting, and
Participants In this phase 1b and 2 basket nonrandomized controlled trial, patients with …